[Myelotoxicity due to cancer chemotherapy with special reference to autologous bone marrow transplantation].
In order to know the myelotoxicity due to combination cancer chemotherapy, the hematologic changes in 15 patients with non-Hodgkin's lymphoma (NHL) treated with combination chemotherapy using adriamycin, cyclophosphamide, vincristine and prednisolone (ACOP protocol) were observed. From this study, it was confirmed that neutrophil leukocyte depletion is one of the most important dose-limiting factors of combination cancer chemotherapy. Our experience of autologous bone marrow transplantation for 15 patients with malignant tumors, such as NHL, small cell lung cancer, nasopharyngeal carcinoma, clearly demonstrated that cryopreserved autologous bone marrow cells can rescue cancer patients from marrow-lethal doses of drugs and irradiation and thus prompts us to establish a new protocol to eradicate tumor cells.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone